EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease (EXecutive)
EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.
Sponsor: Abbott Medical Devices
Listed as NCT00531011, this PHASE4 trial focuses on Coronary Artery Disease and Coronary Artery Restenosis and remains completed. Sponsored by Abbott Medical Devices, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Agrigento, Italy , Bologna, Italy , Catania, Italy , Catanzaro, Italy , Foggia, Italy , Genova, Italy , Mantova, Italy , Milan, Italy , Napoli, Italy , Roma, Italy and 7 more locations